Stott, A. J., Maillard, M. C., Beaumont, V., Allcock, D., Aziz, O., Borchers, A. H., . . . Dominguez, C. (2021). Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease. ACS Med Chem Lett.
Citação norma ChicagoStott, Andrew J., et al. "Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease." ACS Med Chem Lett 2021.
MLA CitationStott, Andrew J., et al. "Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease." ACS Med Chem Lett 2021.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.